Windward Bio is a clinical-stage biotechnology company focused on developing treatments for advanced immunological conditions. The company's lead program, WIN378, is a long-acting anti-TSLP monoclonal antibody currently in Phase 2 trials for asthma. Windward Bio is building a pipeline of long-acting bispecific antibodies targeting validated biology in respiratory and dermatological diseases.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many immunological diseases, including severe respiratory conditions like asthma and COPD, lack effective treatments that address the underlying inflammatory pathways. Current therapies may not adequately target key cytokines involved in disease progression, leading to suboptimal outcomes for patients.
Solution
Windward Bio is a clinical-stage biopharmaceutical company developing novel monoclonal antibodies and bispecific programs to treat advanced immunological diseases. Their lead candidate, WIN378, is a recombinant, fully human monoclonal antibody that potently binds to thymic stromal lymphopoietin (TSLP), a validated cytokine that drives inflammation in asthma, COPD, and other immunological disorders. WIN378 is engineered for an extended half-life and effector silencing and is administered subcutaneously. By inhibiting TSLP, WIN378 aims to address a broad range of inflammatory phenotypes and improve outcomes for patients with severe respiratory conditions. The company is also creating novel, long-acting bispecific programs for immunological diseases.
Target Audience
The primary target audience includes individuals suffering from advanced immunological diseases, particularly severe asthma and COPD, as well as the physicians who treat these conditions.
Features
- WIN378: A novel, recombinant, fully human monoclonal antibody targeting TSLP
- Engineered for extended half-life to allow for less frequent subcutaneous administration
- Effector silencing to minimize off-target effects
- Potential application in a wide array of immunological diseases, including asthma and COPD
- Advancing WIN378 into Phase 2 clinical development
- Creating novel, long-acting bispecific programs for immunological diseases